强生Johnson&Johnson（JNJ）2026第一季度其他财务信息披露「NYSE」（英文版）（13页）.pdf

1、Table 1:Sales by Segment 1Table 2:Sales by Geographic Area2Table 3:Sales of Key Products/Franchises3-7Table 4:Condensed Consolidated Statement of Earnings-QTD8Table 5:Non-GAAP Adjusted Operational Sales Growth-QTD9Table 6:Non-GAAP Adjusted Net Earnings10Table 7:Non-GAAP P&L by Segment Reconciliation

2、 2026-QTD11Table 8:Non-GAAP P&L by Segment Reconciliation 2025-QTD12First Quarter 2026Other Financial DisclosuresTable of ContentsJohnson&Johnson and SubsidiariesSupplementary Sales Data(Unaudited;Dollars in Millions)20262025TotalOperationsCurrencySales to customers bysegment of businessInnovative M

3、edicine U.S.8,871$8,092 9.6%9.6 -International6,555 5,781 13.4 4.3 9.1 15,426 13,873 11.2 7.4 3.8 MedTech U.S.4,459 4,213 5.9 5.9 -International4,177 3,807 9.7 3.2 6.5 8,636 8,020 7.7 4.6 3.1 U.S.13,330 12,305 8.3 8.3 -International10,732 9,588 11.9 3.9 8.0 Worldwide24,062$21,893 9.9%6.4 3.5 Note:Pe

4、rcentages have been calculated using actual,non-rounded figures and,therefore,may not recalculate precisely.FIRST QUARTER Percent ChangeJohnson&Johnson and SubsidiariesSupplementary Sales Data(Unaudited;Dollars in Millions)20262025TotalOperationsCurrencySales to customers bygeographic areaU.S.13,330

5、$12,305 8.3%8.3 -Europe5,848 5,110 14.52.7 11.8 Western Hemisphere excluding U.S.1,293 1,167 10.8 2.5 8.3 Asia-Pacific,Africa3,591 3,311 8.5 6.1 2.4 International10,732 9,588 11.9 3.9 8.0 Worldwide24,062$21,893 9.9%6.4 3.5 Note:Percentages have been calculated using actual,non-rounded figures and,th

6、erefore,may not recalculate precisely.FIRST QUARTERPercent ChangeREPORTED SALES vs.PRIOR PERIOD($MM)FIRST QUARTERINNOVATIVE MEDICINE SEGMENT(2)20262025ReportedOperational(1)CurrencyONCOLOGYUS3,615$3,013 20.0%20.0%-Intl3,358 2,664 26.0%15.3%10.7%WW6,973 5,678 22.8%17.8%5.0%DARZALEXUS2,208 1,829 20.7%